Compare VELO & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | STRO |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | 134 | 131 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 338.9M |
| IPO Year | N/A | N/A |
| Metric | VELO | STRO |
|---|---|---|
| Price | $13.37 | $36.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $18.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.4M | 249.9K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.22 | N/A |
| Revenue Next Year | $50.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $0.67 |
| 52 Week High | $23.84 | $39.10 |
| Indicator | VELO | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 70.25 |
| Support Level | $12.39 | $31.61 |
| Resistance Level | $15.92 | N/A |
| Average True Range (ATR) | 1.64 | 2.88 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 37.99 | 78.22 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.